Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RNASE1 | P07998 | 1/20 | 0.41 |
| ▸ | TYMP | P19971 | 1/20 | 0.41 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.40 |
| ▸ | TYMS | P04818 | 2/20 | 0.38 |
| ▸ | TK2 | O00142 | 1/20 | 0.36 |
| ▸ | TK1 | P04183 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5475154 | 0.89 | RNASE1 (0.53) | RNASE1TK2TK1 | |
| SCHEMBL5489351 | 0.89 | RNASE1 (0.53) | RNASE1TK2TK1 | |
| SCHEMBL5475148 | 0.89 | RNASE1 (0.53) | RNASE1TK2TK1 | |
| SCHEMBL30976656 | 0.89 | RNASE1 (0.53) | RNASE1TK2TK1 | |
| SCHEMBL5489355 | 0.89 | RNASE1 (0.53) | RNASE1TK2TK1 | |
| SCHEMBL9810774 | 0.88 | TK1 (0.43) | RNASE1TYMPTK1 | |
| SCHEMBL9810769 | 0.88 | TK1 (0.43) | RNASE1TYMPTK1 | |
| SCHEMBL9811608 | 0.85 | TK1 (0.41) | RNASE1TK1 | |
| SCHEMBL4167484 | 0.84 | TYMP (0.56) | TYMPTYMS | |
| SCHEMBL4170246 | 0.84 | HSP90AA1 (0.45) | RNASE1TYMPHSP90AA1TYMSTK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090004137-A1 | Uridine Derivatives as Antiviral Drugs Against a Flaviviridae, Especially Hcv | INSTITUTE NATIONAL DE LA SAINTE ET DE LA RECHDERCHE MEDICALE (FR) | 2009-01-01 | — | — | US | disclosed |
| EP-1827457-A1 | URIDINE DERIVATIVES AS ANTIVIRAL DRUGS AGAINST A FLAVIVIRIDAE, ESPECIALLY HCV | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 2007-09-05 | — | — | EP | disclosed |
| WO-2006067606-A1 | URIDINE DERIVATIVES AS ANTIVIRAL DRUGS AGAINST A FLAVIVIRIDAE, ESPECIALLY HCV | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 2006-06-29 | — | — | WO | disclosed |
| EP-1674104-A1 | Uridine derivatives as antiviral drugs against a flaviviridae, especially HCV | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 2006-06-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090004137-A1 | Uridine Derivatives as Antiviral Drugs Against a Flaviviridae, Especially Hcv | NUDT1, UMPS, UPP1 | RNASE1 255/4885TYMP 68/4885HSP90AA1 3549/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.